Despite increasing success of percutaneous coronary interventions, there exists a subset of patients whose angina continues to be refractory to conventional medical and interventional therapies. Apart from standard guideline directed medical therapy, Ranolazine is the only drug approved for treatment for refractory angina. This article discusses the clinical pharmacology of Ranolazine and its role in the management of refractory angina.
